RENAL EFFECTS OF RAPAMYCIN IN THE SPONTANEOUSLY HYPERTENSIVE RAT

被引：28

作者：

DIJOSEPH, JF

MIHATSCH, MJ

SEHGAL, SN

机构：

[1] Inflammation/Bone Metabolism Division, Wyeth-Ayerst Research, Princeton, 08543, NJ

[2] Institute of Pathology, University of Basel, Basel

来源：

TRANSPLANT INTERNATIONAL | 1994年 / 7卷 / 02期

关键词：

RAPAMYCIN; RAT; RENAL FUNCTION; SPONTANEOUSLY HYPERTENSIVE RAT;

D O I：

10.1007/BF00336467

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

The effects of rapamycin (RAPA), administered at therapeutic doses, were investigated in the spontaneously hypertensive rat (SHR). Additionally, the reversibility of RAPA's renal effects was investigated at a supratherapeutic dose. At doses that were active in preventing heart and kidney allograft rejection in the rat (0.01-0.08 mg/kg i.v.), RAPA had no effect on kidney function or rat body weight gain. At higher doses (0.8 mg/kg), RAPA produced significant changes in kidney function parameters and caused a loss in body weight. Histopathologic changes, including necrotizing vasculopathy and tubular atrophy, were noted at therapeutic doses. The effects of RAPA on kidney function were completely reversible after a 2-week washout period, though the histopathologic changes were still evident. These studies demonstrate that RAPA does not impair kidney function at therapeutic doses when administered for 2 weeks but does appear to accelerate the naturally occurring renal lesions of the SHR.

引用

页码：83 / 88

页数：6

共 22 条

[1]

Alessiani M., Cillo U., Fung J., Irish W., Abu-Elimagd K., Jain A., Takaya D., van Thiel D., Starzl T.E., Major adverse effect of FK506 used as an immunosuppressive agent after liver transplantation, Transplant Proc, 25, pp. 628-634, (1993)

[2]

Chang J.Y., Sehgal S.N., Bansbach C.C., FK506 and rapamycin: novel pharmacological probes of the immune response, Trends Pharmacol Sci, 12, pp. 218-223, (1991)

[3]

Chung J., Kuo C.J., Crabtree G.R., Blenis J., Rapamycin — FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinase, Cell, 69, pp. 1227-1236, (1992)

[4]

DiJoseph J.F., Sehgal S.N., Functional and histopathologic effects of rapamycin on mouse kidney, Immunopharmacology and Immunotoxicology, 15, pp. 45-56, (1993)

[5]

DiJoseph J.F., Mihatsch M.J., Chang J.Y., Effect of rapamycin on kidney function in the female spontaneously hypertensive rat, J Am Soc Nephrol, 2, (1991)

[6]

DiJoseph J., Mihatsch M., Wojdan A., Sehgal S., Kidney effects of rapamycin (RAPA) at therapeutic doses, J Amer Soc Nephrol, 3, (1992)

[7]

DiJoseph J., Sharma R.N., Chang J.Y., The effect of rapamycin on kidney function in the Sprague-Dawley rat, Transplantation, 53, pp. 507-513, (1992)

[8]

DiJoseph J., Mihatsch M.J., Sehgal S.N., Influence of rat strain on rapamycin's kidney effects, Transplant Proc, 25, pp. 714-715, (1993)

[9]

DiJoseph J.F., Russo R.J., Cochran D.W., Osmotic pump delivery of rapamycin, Transplantation, 55, pp. 450-452, (1993)

[10]

Dumont F.J., Staruch M.J., Koprak S.L., Siekierka J.J., Lin C.S., Harrison R., Sewell T., Kindt V.M., Beattie T.R., Wyvratt M., Sigal N.H., The immunosuppressive and toxic effects of FK506 are mechanistically related: pharmacology of a novel antagonist of FK506 and rapamycin, J Exp Med, 176, pp. 751-760, (1992)

← 1 2 3 →